Neuronal Nitric Oxide Synthase in Heart Rate Regulation

Pitayadet Jumrusrikiul, Jay Dinerman, Ted M. Dawson, Valina L. Dawson, Ulf Ekelund, Dimitrios Georgakopoulos, Lawrence P. Schramm, Hugh Calkins, Solomon H. Snyder, Joshua M. Hare, and Ronald D. Berger

Department of Medicine, Department of Neurology, Department of Neuroscience, Department of Physiology, and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland 21287

Rapid Publication

Interaction Between Neuronal Nitric Oxide Synthase and Inhibitory G Protein Activity in Heart Rate Regulation in Conscious Mice

Abstract

Nitric oxide (NO) synthesized within mammalian sinoatrial cells has been shown to participate in cholinergic control of heart rate (HR). However, it is not known whether NO synthesized within neurons plays a role in HR regulation. HR dynamics were measured in 24 wild-type (WT) mice and 24 mice in which the gene for neuronal NO synthase (nNOS) was absent (nNOS−/− mice). Mean HR and HR variability were compared in subsets of these animals at baseline, after parasympathetic blockade with atropine (0.5 mg/kg i.p.), after β-adrenergic blockade with propranolol (1 mg/kg i.p.), and after combined autonomic blockade. Other animals underwent pressor challenge with phenylephrine (3 mg/kg i.p.) after β-adrenergic blockade to test for a baroreflex-mediated cardioinhibitory response. The latter experiments were then repeated after inactivation of inhibitory G proteins with pertussis toxin (PTX) (30 μg/kg i.p.). At baseline, nNOS−/− mice had higher mean HR (711±8 vs. 650±8 bpm, P = 0.0004) and lower HR variance (424±70 vs. 1,112±174 bpm2, P = 0.001) compared with WT mice. In nNOS−/− mice, atropine administration led to a much smaller change in mean HR (−2±9 vs. 49±5 bpm, P = 0.0008) and in HR variance (64±24 vs. −903±295 bpm2, P = 0.02) than in WT mice. In contrast, propranolol administration and combined autonomic blockade led to similar changes in mean HR between the two groups. After β-adrenergic blockade, phenylephrine injection elicited a fall in mean HR and rise in HR variance in WT mice that was partially attenuated after treatment with PTX. The response to pressor challenge in nNOS−/− mice before PTX administration was similar to that in WT mice. However, PTX-treated nNOS−/− mice had a dramatically attenuated response to phenylephrine. These findings suggest that the absence of nNOS activity leads to reduced baseline parasympathetic tone, but does not prevent baroreflex-mediated cardioinhibitory response unless inhibitory G proteins are also inactivated. Thus, neurally derived NO and cardiac inhibitory G protein activity serve as parallel pathways to mediate autonomic slowing of heart rate in the mouse. (J. Clin. Invest. 1998. 102:1279–1285.) Key words: nitric oxide • G protein • autonomic nervous system • parasympathetic • baroreflex
The next day, pertussis toxin (PTX) was administered, and ECG recordings were obtained after 1 min. Recordings from those used in the first protocol. After collecting baseline ECG recordings on a different day, 14 WT and 11 nNOS−/− mice received propranolol 1 mg/kg i.p. ECG recordings were again obtained after 10 min of intraperitoneal injection of these pharmacologic agents, after which little additional change in HR was observed.

Protocol 2: Baroreflex HR modulation. The inhibitory limb of the HR baroreflex was studied in four WT and six nNOS−/− instrumented mice in the fully conscious state. These 10 animals were different from those used in the first protocol. After collecting baseline ECG recordings, animals were given propranolol 1 mg/kg i.p., and ECG recordings were repeated 10 min later. Phenylephrine 3 mg/kg i.p. was then administered, and ECG recordings were obtained after 1 min. The next day, pertussis toxin (PTX) 30 μg/kg i.p. was administered to inactivate inhibitory guanine nucleotide proteins (G1 and G3) in cardiac tissue (22). 3 d later, the protocol of propranolol and phenylephrine injections was repeated.

Protocol 3: Acute blood pressure and baroreceptor sensitivity. We did not attempt to measure blood pressure in the chronically instrumented animals in protocols 1 and 2. However, in another four WT and six nNOS−/− mice, baseline blood pressure and baroreceptor sensitivity were measured acutely under anesthesia. Baroreceptors were initially made on a 129SvEv agouti and C57B6 background, we used both 129SvEv and C57B6 WT mice as controls.

In 20 WT and 18 nNOS−/− mice, an electrocardiographic transmitter (Data Sciences Int., St. Paul, MN) with subcutaneous leads was implanted in the peritoneal cavity using aseptic technique under anesthesia with phenobarbital 1 mg i.p. Mice were allowed to recover for 5–10 d before undergoing experimental protocols. All animals were maintained in accordance with the guidelines of the Animal Care and Use Committee at Johns Hopkins and the Guide for the Care and Use of Laboratory Animals (Department of Health and Human Services publication No. NIH 83-23, revised 1985).

Results

Baseline HR dynamics. Results from the first protocol showed that compared with WT mice, nNOS−/− mice had a significantly higher mean HR (711±8 vs. 650±8 bpm, P = 0.0004) and lower HR variance (424±70 vs. 1,112±174 bpm², P = 0.001). These data are shown in Fig. 1.

Autonomic blockade. The effects of parasympathetic, sympathetic, and combined autonomic blockade on mean HR and HR variability are shown in Fig. 2. Compared with the effect in WT mice, in nNOS−/− mice atropine administration led to a much smaller change in mean HR (−2±9 vs. 49±5 bpm, P = 0.0008) and in HR variance (64±24 vs. −903±295 bpm², P = 0.02). By contrast, propranolol administration led to similar changes in mean HR (−84±11 vs. −84±18 bpm, P = NS) in the two groups, although the change in HR variance was greater in WT mice (46±95 vs. −462±231 bpm², P = 0.02). Combined autonomic blockade also caused a similar fall from baseline in mean HR between the two groups (−92±30 vs. −63±22 bpm, P = NS), but it elicited a greater fall in HR variance in the WT mice (−226±132 vs. −1,259±352 bpm², P = 0.02).

Baroreflex pressor response. Protocol 2 was designed to enable investigation of the baroreceptor-mediated HR response to a pressor challenge. Since muscarinic-cholinergic effects are dependent on G1 and G3 activity, we examined the HR response to phenylephrine in WT and nNOS−/− mice both in the setting of intact G protein activity and after G1 and G3 inactivation by administration of PTX. The pressor challenge was performed after β-adrenergic blockade so that any observed change in HR mean or variability would be due to activation of the inhibitory limb of the baroreflex and not the result of sympathetic withdrawal.

Fig. 3 shows the response in WT and nNOS−/− mice to injections of phenylephrine, before and after treatment with PTX. Changes in HR mean and variance resulting from phenylephrine injection were measured relative to the β-adrenergic blocked state. In WT mice, phenylephrine injection elicited a fall in mean HR, which was partially attenuated after PTX treatment (−299±36 vs. −196±35 bpm, P = 0.04), and a rise in HR variance that was similar before and after G protein inactivation (1,654±461 vs. 1,452±564 bpm², P = NS). Phenylephrine elicited a response in nNOS−/− mice before PTX ad-
ministration similar to that in WT mice (mean HR change $284 \pm 11$ bpm, HR variance change $1,481 \pm 386$ bpm$^2$, $P = \text{NS}$ in both parameters compared with WT mice). However in PTX-treated nNOS$^{-/-}$ mice, phenylephrine elicited a much smaller change in mean HR ($-106 \pm 26$ bpm) and HR variance ($107 \pm 73$ bpm$^2$) than in either PTX-treated WT mice ($P = 0.04$ for mean HR, $P = 0.001$ for HR variance) or nNOS$^{-/-}$ mice with intact G protein activity ($P = 0.002$ for mean HR, $P = 0.001$ for HR variance).

**Acute blood pressure measurements.** In the acutely instrumented anesthetized state, baseline systolic blood pressure was similar in the two groups ($77 \pm 6$ mmHg in nNOS$^{-/-}$ mice vs. $87 \pm 6$ mmHg in WT mice, $P = \text{NS}$). With phenylephrine administration, systolic blood pressure rose identically ($17 \pm 7$ mmHg in nNOS$^{-/-}$ mice vs. $17 \pm 4$ mmHg in WT mice, $P = \text{NS}$), and the HR fell by similar amounts ($82 \pm 18$ bpm in nNOS$^{-/-}$ mice vs. $67 \pm 10$ bpm in WT mice, $P = \text{NS}$). The calculated baroreceptor sensitivity was also not significantly different ($7.1 \pm 3.3$ bpm/mmHg in nNOS$^{-/-}$ mice vs. $5.0 \pm 1.6$ bpm/mmHg in WT mice, $P = \text{NS}$).

**Discussion**

To our knowledge, this is the first study to evaluate the role of neuronally derived NO in autonomic HR regulation. Our use of mice with a targeted disruption of the nNOS gene allowed us to distinguish the effects of NO synthesized in neurons from those due to NO produced in the sinus node, myocardium, and vasculature. This model also enabled investigation of the role of NO in autonomic activity without the need for administration of nonspecific NOS inhibitors, whose effects are protean. Importantly, mice were studied in the intact conscious state so that autonomic function could be observed free of the confounding effects of anesthetic agents as well. A similar approach was used by Mansier et al., who studied HR variability in freely moving transgenic mice overexpressing atrial $\beta_1$-adrenoceptors (19), and by Uechi et al., who studied transgenic mice overexpressing cardiac $G_{\text{os}}$ (20).

The main findings of this study are that (a) nNOS activity mediates an inhibitory effect on sinus rate in the mouse at baseline, (b) an inhibitory effect on sinus rate can be elicited by the baroreflex even in mice with a targeted disruption for the nNOS gene, and (c) inactivation of inhibitory G proteins results in partial blunting of the HR baroreflex, while (d) absence of both nNOS activity and inhibitory G protein activity leads to near abolition of baroreflex HR inhibition. Collectively, these findings suggest nNOS activity and cardiac inhibitory G protein activity work in parallel to reduce sinus nodal rate and mediate HR variability. A role for NO in the mediation of cardioinhibitory mechanisms has been suggested by

**Figure 1.** Mean HR (a) and HR variance (b) in WT and nNOS$^{-/-}$ mice. *$P < 0.05$ compared with WT.

**Figure 2.** Change in mean HR (a) and HR variance (b) in WT and nNOS$^{-/-}$ mice after atropine, propranolol, and combined autonomic blockade. *$P < 0.05$ compared with WT.
others (11, 12), but the relationship between nNOS activity and cholinergic regulation of HR has not been explored previously.

**Baseline effects of neuronal NO on HR.** In the baseline state, nNOS \(^{-/-}\) mice had higher mean HR and lower HR variance than WT mice had. While the elevated mean HR could reflect either increased sympathetic or reduced parasympathetic tone, the diminished HR variance strongly suggests the latter. HR variability has been shown to depend on fluctuations in both sympathetic and parasympathetic tone.

In baseline cardiac parasympathetic activity in the nNOS \(^{-/-}\) mice appears to be the result of an alteration in the efferent limb of the baroreflex, either centrally or at the end organ (i.e., sinus node).

**Interaction between inhibitory G proteins and neuronal NO.** After finding that mice lacking nNOS activity had reduced baseline parasympathetic tone, we tested whether an increase in parasympathetic tone could be elicited in these mice by activation of the baroreflex. To exclude the effects of baroreceptor-mediated synaptic withdrawal, baroreflex activation in the chronically instrumented animals was performed after \(\beta\)-adrenergic blockade. We found that with administration of the pressor agent phenylephrine, nNOS \(^{-/-}\) mice exhibited a fall in mean HR and an increase in HR variance equal to those in WT mice. These findings are in concert with those obtained in the acutely instrumented anesthetized mice and suggest that the absence of nNOS activity does not prevent a typical baroreflex-mediated rise in parasympathetic tone.

We then tested whether the pressor response depends on intact G protein activity, and found a striking difference between conscious nNOS \(^{-/-}\) and WT mice after G\(_i\) and G\(_o\) inactivation with PTX. At baseline, inhibitory G protein inactivation led to a slight increase in mean HR and decrease in HR variance in both WT and nNOS \(^{-/-}\) mice. With phenylephrine administration, the PTX-treated WT mice exhibited a blunted decrease in mean HR and a near normal rise in HR variance, while the PTX-treated nNOS \(^{-/-}\) mice had a dramatically at-
tenuated response. In fact, the PTX-treated nNOS−/− mice had nearly complete abolition of HR variability after β-adrenergic blockade, and they exhibited almost no subsequent increase in HR variability after phenylephrine injection. These findings suggest that enhancement in parasympathetic tone elicited by the baroreflex requires either intact cardiac G protein activity or the presence of neurally derived NO, but does not require the presence of both.

The known pathway for cholinergic modulation of HR begins with release of acetylcholine from vagal nerve terminals that impinge on sinus nodal cells. Acetylcholine binds to the muscarinic receptor, causing activation of G proteins Gi and Go, leading to both direct effects on membrane-bound ion channel proteins and indirect effects coupled to adenylyl cyclase inhibition and other cytosolic pathways (32). Gi and Go inhibit the hyperpolarization-activated pacemaker current If through both direct and indirect effects (33), and Gi inhibits L-type calcium current ICa(L) through its effect on adenylyl cyclase (34), both resulting in decreased sinus nodal firing rate. Muscarinic activation also inhibits sinoatrial automaticity through modulation of the polarizing acetylcholine-activated potassium channel IK(ACh) (35), although it is not known whether Gi is the G protein that couples this effect to the muscarinic receptor.

PTX has been shown to inactivate Gi and Go, by catalyzing ADP ribosylation of these proteins (22), resulting in a potent anticholinergic effect on HR regulation (36). We found a rise in mean HR and a fall in HR variability at baseline in both WT and nNOS−/− mice with PTX administration, consistent with an anticholinergic effect. Surprisingly, however, the PTX-treated WT mice exhibited a significant (although partially attenuated) fall in mean HR and a normal rise in HR variance with pressor challenge. Thus, in the mouse, baroreflex activation alters HR dynamics in a manner consistent with enhanced vagal tone, even in the absence of cardiac inhibitory G protein activity.

Based on our findings in the WT mice alone, several mechanisms may be postulated to explain the partially preserved baroreflex after PTX administration. Gi and Go inactivation might have been incomplete, muscarinic activation of other G proteins might have mediated the observed cardioinhibition, or some alternative pathway may participate in the efferent limb of the baroreflex. Data from the nNOS−/− mice provide insight into the likely mechanism. Since pressor-induced cardioinhibition was nearly absent in the PTX-treated nNOS−/− mice, nNOS activity must be responsible for the pressor-induced change in HR dynamics observed in the PTX-treated WT mice. If inhibitory G protein inactivation were merely incomplete or another non–nNOS-dependent mechanism mediated the preserved baroreflex in the PTX-treated WT mice, then the same effects should have been present in the nNOS−/− mice.

NO within the central nervous system has been shown to modulate baroreflex-mediated sympathetic nerve activity (4, 21, 37), so abnormal baroreflex function in the nNOS−/− mice might have been expected. Despite this, we found no significant differences between WT and nNOS−/− mice in baseline blood pressure or baroreflex sensitivity in the anesthetized acutely instrumented state. In addition, we found that in the awake β-adrenergic blocked state, nNOS−/− mice exhibited nearly normal pressor-induced HR changes until inhibitory G proteins were inactivated. This suggests that in the mouse neurally derived NO participates in the efferent limb of autonomic cardioinhibition in a fashion that is independent of β-adrenergic activity and that bypasses the inhibitory G protein pathway.

Recently, Han et al. proposed a model for cholinergic HR modulation in which inhibitory G protein activity and NO provide parallel cytosolic pathways within sinus nodal cells to couple the muscarinic receptor to ion channel function (29). In their model, Gi exerts its effects through inhibition of adenylyl cyclase, while NO, synthesized within sinus nodal cells presumably by endothelial NOS, stimulates soluble guanylyl cyclase. Both of these effects lead to reduced L-type calcium current, resulting in diminished cellular automaticity. We hypothesize that NO, synthesized by nNOS in vagal nerve fibers, diffuses from vagal cells into sinus nodal cells to mediate the NO effects on HR, as schematized in Fig. 4. NO may also interact with cholinergic signaling by potentiating the release of acetylcholine from vagal nerve terminals. Lack of this potentiation in nNOS−/− mice would explain their apparent loss of resting parasympathetic tone and minimal response to atropine in the baseline state.

The concept of NO acting as a neurotransmitter is not new, as there is evidence that NO produced in myenteric neurons diffuses into smooth muscle cells of the intestines and modulates intestinal relaxation (17). A similar mechanism may be present in cardiac ganglia. Sosunov et al. have shown by immunocytochemical analysis that neurons within cardiac ganglia of the rat and guinea pig contain NOS (38). They further argue,  

![Neuronal Nitric Oxide Synthase in Heart Rate Regulation](1283)
on the basis that NOs and vasoactive intestinal peptide are colocalized in some cardiac nerve fibers (39, 40), that NOs-immunoreactive nerves in the heart are parasympathetic in origin. If parasympathetic nerve cells impinging on or within the heart represent a significant source of NO in the mouse, then the parallel actions of NO and inhibitory G proteins proposed in Fig. 4 could explain the observed difference in baroreflex-mediated HR changes between WT and nNOS−/− mice after inhibitory G protein inactivation.

As an alternative explanation for our findings, NO may act centrally within the cardioinhibitory center of the brainstem, although this mechanism would require participation by a second messenger other than G, in order to explain the presence of a pressor response, even if blunted, in the PTX-treated WT mice. Of note, we did not test whether pressor-induced cardioinhibition in WT mice after PTX administration would be abolished by atropine. Thus, it remains unclear whether the cardioinhibitory effect of neurally derived NO requires intact muscarinic receptor function. This unresolved issue awaits clarification with further study.

Limitations. In our interpretation of the results of pharmacologic blockade, we assumed complete effect of the atropine, propanolol, and PTX dosages used, although we did not specifically test for the completeness of blockade. While the dosages we used were similar to those used by others to achieve complete autonomic or G protein blockade (19, 20, 22), it is possible that the WT and nNOS−/− mice had differential sensitivities to these agents, which could have confounded our findings. In addition, in this study we did not consider interactions between cholinergic signaling and the α-adrenergic system, the latter of which may also be influenced by the presence or absence of nNOS activity.

This study is also limited by the imperfections in HR variability analysis. The work assumes that changes in autonomic tone are accurately reflected in the sinus nodal rate. Conceivably, nNOS−/− mice may have altered sinus node function independent of changes in autonomic activity. However, this appears unlikely since the intrinsic rate of the sinus node did not differ significantly between WT and nNOS−/− mice. In addition, in the setting of intact inhibitory G protein activity, pressor challenge elicited the same change in HR mean and variance in the nNOS−/− mice as in WT mice, further supporting intact sinus nodal function in the nNOS−/− mice. Therefore, the presence or absence of nNOS activity is important to the interpretation of the data.

Conclusions. By studying HR dynamics in this conscious transgenic mouse model, we have found a role for neurally derived NO in parasympathetic HR regulation. Absence of nNOS activity leads to reduced baseline parasympathetic tone, but does not prevent baroreflex-mediated cardioinhibition unless cardiac inhibitory G proteins are concomitantly inactivated. These findings provide evidence for parallel pathways of cardioinhibition using nNOS activity on the one hand, and inhibitory G protein activity on the other.

Acknowledgments

The nNOS−/− breeding colony used in this study was obtained through a collaborative agreement between Johns Hopkins University and Massachusetts General Hospital. The mice were originally made by homologous recombination in the laboratories of Drs. Paul Huang and Marc Fishman.

R. Berger is the recipient of a FIRST Award from the National Institutes of Health (HL-54584) and is a Solo Cup Clinician Scientist.

T. Dawson is an Established Investigator of the American Heart Association and is supported by US Public Health Service (USPHS) grant NS33277 and the Paul Beeson Physician’s Faculty Scholar Award. V. Dawson is supported by the American Heart Association and USPHS grant NS33142. S. Snyder is supported by USPHS grant MH18501 and Research Scientist Award DA00074. J. Hare is supported by USPHS grant K08 HL03228 and a grant-in-aid from the American Heart Association.

References


